![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 34, 26441-26448, August 25, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, April 9, 2000
The Ras guanine-nucleotide exchange factor
Ras-GRF/Cdc25Mn harbors a complex array of structural
motifs that include a Dbl-homology (DH) domain, usually found in
proteins that interact functionally with the Rho family GTPases, and
the role of which is not yet fully understood. Here, we present
evidence that Ras-GRF requires its DH domain to translocate to the
membrane, to stimulate exchange on Ras, and to activate
mitogen-activated protein kinase (MAPK). In an unprecedented fashion,
we have found that these processes are regulated by the Rho family
GTPase Cdc42. We show that GDP- but not GTP-bound Cdc42 prevents
Ras-GRF recruitment to the membrane and activation of Ras/MAPK,
although no direct association of Ras-GRF with Cdc42 was detected. We
also demonstrate that catalyzing GDP/GTP exchange on Cdc42 facilitates
Ras-GRF-induced MAPK activation. Moreover, we show that the
potentiating effect of ionomycin on Ras-GRF-mediated MAPK stimulation
is also regulated by Cdc42. These results provide the first evidence
for the involvement of a Rho family G protein in the control of the
activity of a Ras exchange factor.
Small GTP-binding proteins function as key molecular switches in
signal transduction routes that convey stimuli received in cell surface
receptors to the nucleus. The Ras family of small GTP-binding proteins
plays an essential role in the regulation of cell growth and
differentiation. Distributing signals to downstream effector pathways,
mainly those mediated by mitogen-activated protein kinase
(MAPK),1
phosphatidylinositol 3-kinase, and Ral-GDS (1). Ras GTPases cycle
between an inactive, GDP-bound state and an active GTP-bound state, and
it is known that this mechanism is controlled by at least two types of
regulatory proteins directly acting on Ras: GAPs
(GTPase-Activating Proteins),
potentiators of the capacity of Ras to hydrolyze GTP, and GEFs
(Guanine nucleotide Exchange Factors) that catalyze the exchange of GDP for GTP, thus
promoting its activation (2).
Ras-GRF/Cdc25mn is a GEF for the Ras family of small
GTP-binding proteins cloned by virtue of its homology with the
Saccharomyces cerevisiae CDC25 gene product that stimulates
nucleotide exchange on S. cerevisiae RAS (3-6). In
mammalians, Ras-GRF is expressed at high levels in brain (3, 5), but it
is also detected in other tissues and cell lines (7). Analysis of
Ras-GRF primary structure reveals the presence of a number of
functional motifs presumably involved in diverse signaling control
mechanisms and protein-protein interactions. As such, the
carboxyl-terminal Cdc25 domain has strong homology with S. cerevisiae CDC25, thus its name, and it has been shown to catalyze
nucleotide exchange on Ras. This domain is also present in other GEFs
for the Ras family (8). In its amino terminus, Ras-GRF contains a Dbl
homology domain (DH) (9) that bears strong resemblance to the
oncoprotein Dbl, a GEF for the GTPase Cdc42 (10). The DH domain is
generally present in GEFs for the Rho family of small G proteins (11) and other proteins such as Ect2 (12) of yet unidentified function but
also believed to be involved in the regulation of the Rho family
GTPases. In Ras-GRF, the DH domain is flanked by two Pleckstrin homology domains (PH) also present in Rho family GEFs and other unrelated proteins. Although suggested to bind phospholipids and play a
role in membrane targeting, the function of the PH domain remains
largely unknown (13).
With regards to the biological role of Ras-GRF and the mechanisms
governing it, it has been shown that Ras-GRF is capable of inducing
cellular transformation in fibroblast (14). Ras-GRF is also involved in
conveying signals from G protein-coupled receptors to Ras (15-17).
Calcium can also regulate Ras-GRF activity by a mechanism mediated
through a calmodulin-binding motif (IQ domain) present in its amino
terminus (18, 19). As such, calcium ionophores like ionomycin can
enhance Ras-GRF-mediated activation of the MAPK pathway (19, 20).
Interestingly, mutations within the DH domain inhibit ionomycin-induced
MAPK activation (21), suggesting that the Ras-GRF DH domain may somehow
function in the regulation of this signaling route.
In this study we have investigated the role of Ras-GRF DH domain in the
activation of the Ras/MAPK pathway. We present evidence that Ras-GRF
requires its DH domain to translocate to the membrane and, in so doing,
become activated. We also demonstrate that, in an unprecedented
fashion, this process is regulated by the GTPase Cdc42 that when
GDP-bound precludes Ras-GRF recruitment to the membrane and the
subsequent activation of the Ras/MAPK pathway.
Constructs--
Ras-GRF mutants: Cell Culture--
COS-7 cells were regularly grown in DMEM
supplemented with 10% fetal calf serum. Subconfluent cells were
transfected by the DEAE-dextran technique (22). The total amount of
plasmid DNA was adjusted to 3-4 µg per plate with vector DNA when necessary.
Transformation Assays--
NIH 3T3 cells were cultured in DMEM
supplemented with 10% calf serum DNA and transfected by the calcium
phosphate precipitation technique (23). After 10-15 days in culture
plates, the cells were stained in 5% Giemsa, and transformed foci were scored.
Kinase Assays--
MAPK and JNK kinase activities were
determined as described previously (24) in anti-HA immunoprecipitates
using myelin basic protein (Sigma) or GST-ATF2 as substrates for MAPK
or JNK, respectively, and incubated at 30 °C for 30 min. Reactions
were terminated by addition of 5× Laemmli buffer, boiled, and
electrophoresed in 12% SDS-polyacrylamide gel electrophoresis gels.
The gels were visualized by autoradiography and quantitated by
PhosphorImager (Molecular Dynamics).
Immunoblotting--
Total lysates were fractionated in
SDS-polyacrylamide gel electrophoresis gels and transferred onto
nitrocellulose filters. Immunocomplexes were visualized by enhanced
chemiluminescence detection (Amersham Pharmacia Biotech), using
horseradish peroxidase-conjugated secondary antibody (Cappel). Mouse
monoclonal anti-AU5 antibody was from Babco. Rabbit polyclonal
antibodies anti-Ras-GRF and anti-Cdc42 were from Santa Cruz
Laboratories. Anti-FLAG antibody was from Eastman Kodak.
Nucleotide Exchange Reactions--
In vivo nucleotide
exchange was determined in COS-7 cells cotransfected with AU5-tagged
GTPases and the different activating constructs as described (25, 26).
Briefly, cells were cultured for 48 h, serum-starved in
phosphate-free DMEM for 18 h, labeled with
[32P]orthophosphate (100 µCi/ml) for 2-6 h and
disrupted in lysis buffer (50 mM Tris-HCl (pH 7.5), 20 mM MgCl2, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl fluoride, 25 µg/ml leupeptin, and 25 µg/ml
aprotinin). Lysates were immunoprecipitated with anti-AU5 antibody for
1 h, and immunocomplexes were recovered using protein G-Sepharose
beads, washed once in lysis buffer, washed twice in 50 mM Tris-HCl (pH 7.5), 20 mM MgCl2, 500 mM NaCl, and resuspended in 1 M
KH2PO4, 5 mM EDTA (pH 8.0). Bound
nucleotides were released by heating and fractionated using polyethyleneimine thin layer chromatography plates.
Subcellular Fractionation--
This was performed in 20 mM HEPES, pH 7.4, buffer, basically as described previously
(21).
GST Fusion Pull-down Assays--
Bacterially synthesized
GST-fusion proteins were purified using standard procedures. 20 µg
were incubated with lysates from cells transfected with Ras-GRF,
basically as described previously (27).
GTP-Cdc42 Pull-down--
AU5 Cdc42-transfected cells were lysed
in: 25 mM HEPES (pH 7.3), 10 mM
MgCl2, 150 mM NaCl, 0.5 mM EGTA, 20 mM Ras and MAPK Activation Induced by Ras-GRF Deletion
Mutants--
To investigate the role of Ras-GRF DH domain in the
activation of the Ras/MAPK pathway, we utilized transient
overexpression as an experimental approach, because most of the
available data on Ras-GRF biochemistry has been obtained by this
method. To begin with, we generated a series of expression plasmids
encoding for deletion mutants of the different domains present in
Ras-GRF, and their expression in COS-7 cells was ascertained by
immunoblotting (Fig. 1A,
top panel). Because the anti-GRF antibody utilized (Santa Cruz) recognizes a carboxyl terminus epitope absent in the Cdc25 deletion mutant (
We first assayed the ability of the deletion mutants to catalyze
GDP/GTP exchange on Ras. For this purpose, the different Ras-GRF
constructs were cotransfected into COS-7 cells together with an
AU5-tagged H-Ras (26), cells were incubated with
[P32]orthophosphate, and nucleotide exchange was scored
in anti-AU5 immunoprecipitates after thin-layer chromatography (see
"Materials and Methods"). As shown in Fig. 1A
(lower panel), deletion of the PH1 and PH2 domains (
It would be conceivable that the observed inactivity of the Effects of the DH Domain Deletion on Cellular Transformation by
Ras-GRF--
The fact that Ras-GRF has been shown to transform murine
fibroblasts (14, 30) prompted us to investigate how the removal of the
DH domain would affect the Ras-GRF ability to induce focus formation.
To do so, we utilized the standard focus-formation assay in NIH 3T3
murine fibroblasts (23). The colonies arising after transfection of NIH
3T3 fibroblasts with Ras-GRF showed a typical "Ras" phenotype (Fig.
2 and data not shown). Nevertheless, Ras-GRF transforming potential, as ascertained by the number of foci
generated upon transfection, was 20-fold less than that exhibited by
Ras V12. Deletion of the PH1 domain did not alter focus-formation induced by Ras-GRF. Surprisingly, Cdc42 Is Required for Ras-GRF Signaling--
Because deletion of
Ras-GRF DH domain had dramatic consequences on the activation of the
Ras/MAPK pathway and because the DH domain is a common structural
feature of proteins that interact with Rho family G proteins (10), we
next explored whether the participation of a Rho family GTPase would be
necessary for Ras activation induced by Ras-GRF. As an approach, we
utilized the Rho family dominant inhibitory mutants analogous to Ras
N17 (31). It was found that Cdc42 N17 caused a 60% reduction on
Ras-GRF-induced GDP/GTP exchange over Ras, almost as much as Ras N17
(Fig. 3A). But Rac and Rho
dominant inhibitory mutants, otherwise capable of blocking JNK
activation in COS-7 and 293T cells respectively (22, 32 and data not
shown), were ineffective. As an additional control, none of
these inhibitory mutants affected MAPK stimulation by an activated MEK
mutant (MEK E) known to act downstream of Ras (33) (Fig.
3B). These results suggested that Cdc42 could be
participating in the activation of the Ras/MAPK pathway by Ras-GRF.
Interestingly, the inhibitory effect exerted by Cdc42 dominant
interfering mutant was specific for Ras-GRF, because it did not affect
the activation of MAPK by another Ras exchange factor such as SOS (Fig.
3C) under the same experimental setting.
Ras-GRF Does Not Interact Directly with Cdc42--
The above
results suggested that there could exist a functional relationship
between Cdc42 and Ras-GRF. This led us to investigate the existence of
a direct interaction between Ras-GRF and Cdc42. In vitro
experiments have revealed that Ras-GRF cannot stimulate guanine
nucleotide exchange in Rho family proteins, including Cdc42 (4). To
confirm if this was the case in vivo, we tested whether
Ras-GRF could promote nucleotide exchange on Cdc42 in COS-7 cells, by
scoring 32P-labeled GDP bound to the GTPases as a method to
evaluate radiolabeled nucleotide incorporation rates (25, 26). We found
that Ras-GRF readily induced GDP/GTP exchange on cotransfected AU5-Ras
but failed to catalyze GTP uptake on AU5 Cdc42, whereas under the same
experimental setting Dbl (10), a bona fide Cdc42 exchange factor, potently stimulated Cdc42 exchange activity (Fig.
4A, top panel).
Thus, verifying in vivo that Ras-GRF is not an exchange factor for Cdc42. This result was further substantiated, as Cdc42 is a
potent activator of Jun amino-terminal kinase (JNK) in COS-7 cells
(22). However, Ras-GRF was unable to induce any JNK activation, whereas
under the same experimental conditions, two exchange factors known to
act on Cdc42, Dbl or Ost (34), markedly stimulated JNK (Fig.
4A, lower panel). Also, we could not detect any
physical association in vitro between Ras-GRF and Cdc42,
when nucleotide-free glutathione S-transferase (GST) fusions
of the Rho family GTPases were incubated with Ras-GRF-transfected COS-7
cell lysates. However, Ras-GRF specifically associated with GST-Ras
under the same setting (Fig. 4B). In a similar fashion, GDP
and GTP Cdc42 and the DH Domain Regulate Ras-GRF Recruitment to the
Membrane Fraction--
It has been previously demonstrated that the
amino-terminal region of Ras exchange factors is critical for
determining their membrane localization (27, 35). Therefore, we then
examined how the deletion of the DH domain affected the subcellular
localization of Ras-GRF. As shown in Fig.
5A, in transfected COS-7 cells
Ras-GRF was evenly distributed between the cytosolic and particulate
fractions. However, Ras-GRF
Interestingly, the effects of the different Cdc42 proteins on Ras-GRF
localization in the particulate fraction, matched their influence over
the Ras-GRF-induced activation of MAPK: Cdc42 N17 caused a 60%
reduction, Cdc42 wild type diminished it by 30%, and MAPK activation
was unaffected by Cdc42 QL (Fig. 5B). These effects could
not be attributed to their expression levels, because they were
similarly expressed (inset in Fig. 5B). The
inhibitory effect of Cdc42 wild type was dose-dependent,
because increasing the amount of cotransfected Cdc42 wild type
gradually decreased Ras-GRF-induced MAPK activation, concomitantly with
the disappearance of Ras-GRF from the particulate fraction and its
accumulation in the cytoplasm (data not shown).
These results suggested that the DH domain might be required for
positioning Ras-GRF in the particulate fraction and, in so doing,
bringing about the activation of the Ras/MAPK pathway. As such, we
reasoned that targeting inactive Ras-GRF
In the same line, we hypothesized that, if Cdc42 N17 would be
inhibiting Ras-GRF-mediated MAPK activation by precluding its recruitment to the particulate fraction, a membrane-targeted Ras-GRF should be insensible to Cdc42 N17 restraint. As reasoned, we found that
activation of MAPK by the membrane-bound Ras-GRF CAAX,
mainly located in the particulate fraction, was unaffected by Cdc42 N17 (Fig. 5D). Therefore, this supports the notion that Cdc42
has a role in directing Ras-GRF to the membrane.
Cdc42 GDP/GTP Exchange Facilitates Ras-GRF-mediated MAPK
Activation--
The experiments described above demonstrated that
Cdc42 wild type and N17, but not QL, blocked MAPK activation by
Ras-GRF. This implied that Cdc42 would be acting as a blocker in the
GDP-bound but not in the GTP-bound state. If this were to be the case,
induction of GDP/GTP exchange on Cdc42 should facilitate
Ras-GRF-mediated MAPK activation. To ascertain this hypothesis, we
cotransfected the Rho family GEFs Dbl and Vav with suboptimal
concentrations of Ras-GRF, not enough to yield MAPK per se.
High concentrations of Cdc42 wt were also cotransfected in order to
make more remarkable any effect exerted by the exchange factors. As
shown in Fig. 6A, Dbl markedly
potentiated Ras-GRF-mediated MAPK activation, whereas Vav, a
Rac-1-specific exchange factor (26), was largely ineffective. On the
other hand, JNK activation by the exchange factors was unaffected by
the presence of Ras-GRF (Fig. 6A). This result suggested that decreasing the amount of GDP-bound Cdc42 promoted MAPK stimulation by Ras-GRF.
The calcium ionophore ionomycin has been shown to greatly potentiate
Ras-GRF activity (19). Our results suggest that GDP-bound Cdc42
inhibits the activation of Ras-GRF. Therefore, to stimulate Ras-GRF,
ionomycin would be expected to alleviate the Cdc42-mediated restraint
by diminishing the levels of GDP-Cdc42, something that could be
accomplished by the induction of GDP/GTP exchange over Cdc42. To test
this hypothesis, we assessed the ionomycin-induced generation of
GTP-bound Cdc42 by specifically capturing it with the aid of a GST-PAK
Rac/Cdc42 binding domain (RBD) fusion (28). For this purpose, COS-7
cells transfected with AU5-Cdc42 were stimulated with ionomycin for 1 min, and this treatment induced the formation of GTP-Cdc42 to the same
extent as in those cells transfected with the Cdc42 exchange factor Dbl
(Fig. 6B). Moreover, the Cdc42 N17 dominant interfering
mutant could markedly diminish Ras-GRF-mediated MAPK activation induced
by ionomycin in a specific fashion, because Rac and Rho inhibitory
mutants failed to affect it (Fig. 6C). This proves that the
stimulatory effect of ionomycin over Ras-GRF activity is dependent on Cdc42.
In this study we have investigated the role of the DH domain in
Ras-GRF biochemical and biological functions. Using a set of deletion
mutants for the different domains harbored in the Ras-GRF regulatory
domain, we show that the amino-terminal PH1 domain is
dispensable for the stimulation of nucleotide exchange on Ras,
MAPK activation, and cellular transformation. This amino-terminal PH
domain is a unique feature in Ras-GRF and has been implicated in the
responsiveness of the protein to calcium signaling. The disruption of
this domain makes Ras-GRF insensible to stimulation by calcium
ionophores (20). However, based in previous (14) and our present
observations, it would not be essential for Ras-GRF basal biochemical activity.
Despite being involved in membrane and cytoskeletal targeting (35, 38),
the function of the second PH domain (PH2), common to all Dbl family
proteins, remains largely unknown. We have found that the deletion of
PH2 does not alter the ability of Ras-GRF to stimulate nucleotide
exchange on Ras or induce MAPK activation. However, it completely
abolishes Ras-GRF focus-forming potential. In agreement, mutations on
SOS PH domain reduce its focal transforming activity, although they
also slightly affect its exchange potential (39). A similar effect is
observed in Dbl, where a PH deletion abrogates its transforming ability
without affecting its in vitro catalytic activity as an
exchange factor for Rho and Cdc42 (38). Moreover, an isolated SOS PH
domain induces germinal vesicle breakdown in Xenopus oocytes
in a cooperative fashion with Ras (40), suggesting that the PH domain
might be mediating GTPase-independent events necessary for inducing
proliferation and/or transformation.
Ras-GRF localizes in the particulate fraction (4, 20 and this study). A
recent report indicates that a mutation on a highly conserved residue
of the PH2 domain, which impairs Ras-GRF responsiveness to calcium,
does not affect the cellular localization of the protein (21). All
these observations lead to speculation that the PH domain could be much
more than a targeting signal, implicated somehow in processes of key
importance in the upbringing of cellular transformation by mechanisms
currently under investigation.
We have observed that deleting the complete DH domain results in a
biologically inactive Ras-GRF, incapable of catalyzing GTP
incorporation on Ras in vivo, activating MAPK, nor inducing cellular transformation. Accordingly, a recent report (41) indicates that a mutation in a critical residue within the DH domain markedly diminishes the ability of Ras-GRF to induce focus formation and to
activate Ras, by precluding Ras-GRF oligomerization. Moreover, Dbl
exchange activity and transformation are impaired by conservative substitutions in a region of seven amino acids that is highly conserved
in most DH domains (42). Also in perfect agreement with our
observations, an in vivo study (39) shows that a similar cluster of mutations was found to diminish MAPK activation and cellular
transformation by SOS. When introduced in Ras-GRF, however, these same
mutations do not affect its exchange activity over Ras in
vitro (21). Although apparently conflicting with our results,
in vitro settings may not always reflect physiological conditions. Indeed, we show that mutations within the DH domain that do
not affect Ras-GRF interaction with Ras in vitro, are biologically inactivating in vivo. On the other hand, the DH
domain seems to be dispensable for the activation of MAPK by
Ras-GRF2 (43), but in this case the DH domain is neither necessary for mediating ionomycin activation, as opposed to Ras-GRF DH domain (21).
So, it is conceivable that despite their high similarities these two
isoforms may be differentially regulated.
Interestingly, we show that ablation of the DH domain prevents Ras-GRF
recruitment to the particulate fraction. But the addition of a
CAAX membrane-targeting signal restores the capability of this mutant to activate MAPK. These results are suggestive of the DH
domain being involved in Ras-GRF recruitment to the membrane, which
would be a requisite for activating the Ras/MAPK pathway. In agreement
with our data, biologically inactivating mutations within the Vav3 DH
domain render cytoplasmic an otherwise membrane-associated protein
(44). The DH domain is a complex motif composed of three conserved
regions interspaced by heterogeneous sequences (9). Thus, it cannot be
discounted that, in addition to catalyzing exchange on Rho proteins,
other regions within this domain could also be involved in up to now
unveiled processes necessary for the biological activity of the
exchange factors, such as regulating cellular localization, as our
results suggest. This can be envisioned by our data showing that
the complete deletion of the DH domain results in a
transformation-defective Ras-GRF. However, a partial DH deletion
maintaining the last 36 residues retains its transforming potential
(14), indicating that this region, in which no known consensus motifs
are found, may entail some functions necessary for Ras-GRF optimal
activity. The portion of the DH domain responsible for targeting
Ras-GRF to the membrane is being investigated.
To date, all Dbl-related proteins are connected, one way or another, to
the Rho family GTPases (11). Our results indicate that Ras-GRF is no
exception, because Cdc42 can profoundly affect its biochemical
activity. We show that wild type and N17 Cdc42 preclude the Ras-GRF
presence in the particulate fraction and activation of the Ras/MAPK
pathway. The fact that a membrane-bound Ras-GRF circumvents Cdc42 N17
inhibitory effects suggests that Cdc42 plays an essential role in the
recruitment of Ras-GRF to the membrane. In this context, we have not
been able to detect any direct binding of Ras-GRF to Cdc42 in
vitro. This however, may be due to the requirement for other
components to form a stable complex and does not rule out that such an
interaction takes place in vivo.
It could be argued that the inhibitory effects of Cdc42 N17 could be
very indirect by inducing profound alterations in the cell
(e.g. in the actin cytoskeleton), in a way that would
prevent Ras-GRF recruitment to the membrane and subsequent Ras/MAPK
activation. This is unlikely, because Rho and Rac dominant
interfering mutants that should also be expected to induce major
cytoskeletal alterations do not affect Ras-GRF function. More
importantly, MAPK activation by SOS is completely unaffected by Cdc42
N17, which speaks in favor of the described Cdc42 inhibitory effects
being specific for Ras-GRF.
The Ras-GRF relationship with Cdc42 does not imply, in any case, that
Ras-GRF should promote nucleotide exchange on the GTPase. As previously
shown in vitro (4, 21) our results provide evidence that
Ras-GRF is not an exchange factor for Cdc42 in living cells. In
agreement, recent reports (45, 46) indicate that serpentine receptor
Surprisingly, although Cdc42 wild type and N17 act as effective
blockers of Ras-GRF membrane localization and MAPK activation, the
constitutively activated mutant Cdc42 QL does not. This implies that
Cdc42 acts as an interfering molecule only when GDP-bound, but not in
the GTP-bound form. In agreement, we show that stimulating the
formation of GTP-Cdc42 with a Cdc42 exchange factor such as Dbl
potentiates Ras-GRF-mediated MAPK activation. The fact that Dbl cannot
activate MAPK per se excludes the possibility of this effect
being due to a Cdc42 > Pak3 > Raf > MEK > MAPK
connection (47) activated by Dbl itself. Moreover, ionomycin, a
stimulator of Ras-GRF (21), induces nucleotide exchange on Cdc42,
suggesting that relieving the blockade exerted by GDP-Cdc42 is
necessary for activating Ras-GRF. Furthermore, Ras-GRF-mediated MAPK
activation stimulated by ionomycin is specifically blocked by Cdc42
N17, verifying that the effects of ionomycin over Ras-GRF are
Cdc42-dependent.
Overall, and based on our presented data, we propose a hypothetical
model that may help to envisage the role of Cdc42 in Ras-GRF activation: GDP-bound Cdc42 may be sequestering a yet unidentified "membrane anchor" protein that Ras-GRF would require to localize in
the membrane. Upon loading Cdc42 with GTP, this interaction would be
relieved thus allowing Ras-GRF to gain access to its membrane
attachment and to activate Ras. Based on our data, the association
between Ras-GRF and its membrane anchor could be mediated by the DH domain.
If found to be true, this model may help explain a long-lasting,
apparent inconsistency: Why are most Rho family GEFs potent oncogenes,
if their only known effectors, the Rho GTPases, are not, even when
mutationally activated (11)? In light of our current hypothesis, this
could be explained by Rho GEFs being capable of promoting a
certain amount of Ras activation upon inducing nucleotide exchange on
the Rho GTPases. This relieves the restraint that GDP-bound Rho
family proteins may be exerting over Ras-specific exchange factors by
sequestering their membrane attachments. In fact, we show that in the
presence of suboptimal concentrations of Ras-GRF, Dbl is capable of
inducing the activation of the Ras/MAPK pathway. Whether this model is
true and applicable to other Ras exchange factors and Rho family
proteins is under current investigation as is the determination of the
identity of the putative membrane anchoring proteins.
We thank L. A. Feig, L. Lim, and X. Bustelo for providing us with reagents and J. León, D. Delgado,
and J. C. Rodriguez for helpful discussion.
*
This work was supported by the Spanish Ministry of Education
(Grant PM 98-0131) and by a grant from Fundación Marcelino
Botín.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
A predoctoral fellow from the Universidad de Cantabria.
Published, JBC Papers in Press, June 5, 2000, DOI 10.1074/jbc.M002992200
The abbreviations used are:
MAPK, mitogen-activated protein kinase;
GEF, guanine nucleotide exchange
factor;
GAP, GTPase-activating protein;
DH, Dbl homology domain;
PH, Pleckstrin homology domain;
bp, base pair(s);
JNK, c-Jun
NH2-terminal kinase;
DMEM, Dulbecco's modified Eagle's
medium;
MEK, mitogen-activated protein kinase/extracellular
signal-regulated kinase kinase;
GST, glutathione
S-transferase;
GTP
The Rho Family GTPase Cdc42 Regulates the Activation of Ras/MAP
Kinase by the Exchange Factor Ras-GRF*
§,
,
§,
¶,
,
,
,
§
Departamento de Biología Molecular,
Universidad de Cantabria, Santander 39011, Spain; the
§ Instituto de Investigaciones Biomedicas, Consejo Superior
de Investigaciones Científicas, Madrid, Spain; and the
** Cell Growth Regulation Section, Oral and Pharyngeal Cancer Branch,
National Institute of Dental Research, National Institutes of Health,
Bethesda, Maryland 20892
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
PH1 (bp 74-460 deleted),
DH (bp 578-1519),
PH2 (bp 1417-1993), and
Cdc25 (bp
1993-3790) were obtained by standard restriction enzyme digestions and
polymerase chain reaction-directed mutagenesis. Sequences of the
oligonucleotides used and the mutation strategies followed are
available upon request. All constructs were in the pCEV mammalian
expression vector background (22).
-glycerophosphate, 0.5% Nonidet P-40, 4%
glycerol, 2 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 25 µg/ml leupeptin, and 25 µg/ml aprotinin. GTP-bound AU5 Cdc42 was affinity-sequestered with
bacterially synthesized GST-PAK Rac/Cdc42 binding domain (RBD) (70-106
amino acids) basically as described (28). Immunoblots were
performed as described above using anti-AU5 antibody.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
Cdc25), we tagged this mutant with an
amino-terminal FLAG epitope to enable its detection (Fig.
1A, right panel).

View larger version (32K):
[in a new window]
Fig. 1.
Effects of the Ras-GRF deletion mutants on
the activation of RAS/MAPK. A, top left,
expression of the Ras-GRF mutants (1 µg) in COS-7 cells. Top
right, expression of FLAG-epitoped
Cdc25. Bottom,
Ras nucleotide exchange in COS-7 cells cotransfected with the Ras-GRF
mutants and AU5-Ras (1 µg). B, MAPK activation by Ras-GRF
deletion mutants (1 µg). Bottom, expression of HA-ERK2.
Data in A and B show average ± S.E.M. of
three independent experiments. C, top, MAPK
activation by Ras-GRF DH domain mutants (1 µg each).
Bottom, Ras-GRF expression levels. D, in
vitro association of Ras-GRF DH domain mutants with Ras. GST-H-Ras
fusion protein or GST alone were incubated with lysates of cells
transfected with the Ras-GRF proteins as indicated. TL,
total lysates.
PH1,
PH2) had no effect on the capacity of Ras-GRF to induce GDP/GTP
exchange on Ras, but the disruption of the DH domain (
DH) decreased
Ras-GRF exchange activity to an extent similar to that caused by
deleting the catalytic Cdc25 domain (
Cdc25). Consequently, we then
determined how the different deletions affected Ras-GRF-induced MAPK
activation, by cotransfecting the mutants with an HA epitope-tagged
form of ERK2 (29). In full agreement with the data above, we found that
there were no significant differences on the activation of MAPK
elicited by the wild type,
PH1, and
PH2 mutants. On the other
hand, MAPK activation was severely diminished on those cells
transfected with the DH domain deletion mutant (Fig.
1B).
DH
mutant could be due to the deletion of the DH domain resulting in a
misfolded, nonfunctional protein. To rule out this possibility, we
assayed the activation of MAPK by another Ras-GRF mutant (DH
) in
which the conserved LTLHELL motif within the DH domain had been
substituted (21) and where no misfolding should be expected. We found
that DH
was also impaired in its ability to activate MAPK (Fig.
1C). Moreover, both the
DH and DH
mutants could
interact in vitro with H-Ras as efficiently as did the wild
type protein (Fig. 1D). This ruled out a misfolded protein
incapable of interacting with Ras as the reason for the inability of
the
DH mutant to stimulate the Ras/MAPK pathway.
PH2 which, as shown above, exhibited an unaltered capacity for inducing Ras GDP/GTP exchange and
MAPK stimulation, was entirely inhibited in its focus-forming activity.
On the other hand, the absence of the DH domain completely abolished
Ras-GRF-induced transformation, just as much as deleting the catalytic
Cdc25 domain (Fig. 2). Overall, these results indicate that the DH
domain is essential for Ras-GRF activation of the Ras/MAPK pathway and
subsequent biological activity.

View larger version (53K):
[in a new window]
Fig. 2.
Effects of Ras-GRF deletion mutants on
cellular transformation. NIH3T3 fibroblast were transfected with
the indicated Ras-GRF deletion mutants (1 µg) and H-Ras V12 (100 ng)
by the calcium phosphate technique. Foci were stained and scored after
2 weeks in culture.

View larger version (29K):
[in a new window]
Fig. 3.
Effects of Rho family GTPases dominant
inhibitory mutants (250 ng) on Ras-GRF signaling. A,
effects on Ras-GRF-induced nucleotide exchange over AU5-Ras.
B, effects on MAPK activation induced by Ras-GRF and MEK E. Data in A and B show average ± S.E.M. of
three independent experiments. C, top, effects of
Cdc42 N17 on MAPK activation induced by Ras exchange factors SOS and
Ras-GRF (1 µg each), cotransfected with (+) or without (
) Cdc42
N17. Bottom, expression levels of Cdc42.
S-loaded Cdc42 did not interact with Ras-GRF either (data not
shown). These results demonstrate that there is no direct functional,
nor physical, relationship between Ras-GRF and Cdc42.

View larger version (35K):
[in a new window]
Fig. 4.
Lack of functional and physical interaction
between Ras-GRF and Cdc42. A, Ras-GRF exchange activity on
Cdc42 in vivo. Top, nucleotide exchange on
AU5-Cdc42 and AU5-Ras induced by the different exchange factors.
Bottom, JNK activation by Rho family exchange factors.
B, in vitro, interaction of Ras-GRF with GST
fusion proteins of the Rho family GTPases, performed as indicated under
"Materials and Methods." The amount of GST-GTPases fusion proteins
utilized in the assay is shown below, as ascertained by anti-GST
immunoblotting.
DH was almost completely absent from the
membranous fraction. Strikingly, whereas Rac N17 and Rho N19 inhibitory
mutants did not affect Ras-GRF cellular distribution, cotransfecting
Cdc42 N17 together with Ras-GRF mimicked the effect of deleting the DH
domain, by preventing the presence of Ras-GRF in the particulate fraction. Wild type Cdc42, which similar to Cdc42 N17 is preferentially GDP-bound under serum starvation conditions utilized in this assay (36), also diminished Ras-GRF recruitment to the particulate fraction.
On the other hand, a constitutively active, GTP-bound, Cdc42 QL (22)
did not alter Ras-GRF distribution (Fig. 5A). The cellular
distribution of Ras-GRF under these circumstances was further
substantiated with the aid of enhanced green fluorescent protein
chimeras in which the Cdc25 domains of wild type and
DH Ras-GRF were
substituted by enhanced green fluorescent protein, generating proteins
clearly visible under the microscope. By this method we could verify
the above-mentioned results: the presence in the membrane of
Ras-GRF wt and its disappearance from this structure upon
cotransfection with Cdc42 N17, resembling the distribution of the
DH
mutant present solely in the cytoplasm (data not shown).

View larger version (14K):
[in a new window]
Fig. 5.
Regulation of Ras-GRF cellular distribution
and function by the DH domain and Cdc42. A, subcellular
distribution of Ras-GRF proteins in COS-7 cells transfected with
Ras-GRF wild type (wt) or Ras-GRF DH deletion mutant
(
DH), in addition to the constructs encoding
for the indicated Rho family proteins, as detected by anti Ras-GRF
immunoblotting. (S) S100 soluble fraction; (P)
P100 particulate fraction. B, effects of Cdc42 wild type
(wt), N17, and QL on MAPK activation induced by Ras-GRF and
Ras V12. Data shows average ± S.E. of three independent
experiments. Inset, Cdc42 protein expression in the
corresponding cellular lysates. C, activation of MAPK by
Ras-GRF
DH-CAAX. Top, subcellular distribution
of
DH-CAAX. Middle, MAPK activation by the
indicated Ras-GRF constructs, including
DH-CAAX.
Bottom, expression of the different Ras-GRF proteins.
D, effects of Cdc42 N17 on MAPK activation by
Ras-GRF-CAAX. Top, subcellular distribution of
Ras-GRF-CAAX. Middle, MAPK activation by
Ras-GRFwt and Ras-GRF-CAAX in the absence (
) or presence
(+) of Cdc42 N17. Bottom, expression levels of Ras-GRF and
Cdc42 N17.
DH to the membrane might
restore its ability to activate MAPK. To ascertain this point, we
engineered a membrane-bound Ras-GRF
DH by the addition of an H-Ras
CAAX box (37) (
DH CAAX). It was found that
this protein, verified to be preferentially located in the membrane
fraction, was capable of potently activating MAPK (Fig. 5C).
Thereby, this proved that the DH domain is involved in Ras-GRF recruitment to the membrane, a requirement for activating MAPK.

View larger version (26K):
[in a new window]
Fig. 6.
Effects of Cdc42 GDP/GTP exchange on
Ras-GRF-mediated MAPK activation. A, effects of Rho
family GEFs on Ras-GRF-mediated MAPK (top) and JNK
(bottom) activation: Dbl and Vav (1 µg each) were
cotransfected without (
) or with (+) suboptimal concentrations of
Ras-GRF (100 ng) in the presence of Cdc42 (3 µg). B,
nucleotide exchange on Cdc42 induced by ionomycin. Cells transfected
with AU5-tagged Cdc42 wild type and QL, as indicated, were stimulated
for 1 min with 5 µM ionomycin or by cotransfection with
Dbl. GTP-bound AU5 Cdc42 was pulled-down with GST-PAK RBD ().
C, effects of the Rho family dominant inhibitory mutants on
ionomycin-induced MAPK activation: constructs encoding for the
different GTPases inhibitory mutants and Ras V12 as indicated, were
cotransfected with (+) or without (
) suboptimal concentrations of
Ras-GRF (100 ng) and stimulated, where indicated, with 5 µM ionomycin for 1 min.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

subunits and Src induce nucleotide exchange activity of Ras-GRF
over Rac-1 but not over Cdc42.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
A fellow from the Deutscher Akademischer Austauchbienst.

To whom correspondence should be addressed: Instituto de
Investigaciones Biomédicas, Consejo Superior de Investigaciones Centíficas, Arturo Duperier, 4 Madrid, 28029, Spain. Tel.:
34-91-5854886; Fax: 34-91-5854587; E-mail: pcrespo@iib.uam.es.
![]()
ABBREVIATIONS
S, guanosine
5'-3-O-(thio)triphosphate.
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
1.
Katz, M. E.,
and McCormick, F.
(1997)
Curr. Opin. Genet. Dev.
7,
75-79
2.
Boguski, M. S.,
and McCormick, F.
(1993)
Nature
366,
643-654
3.
Martegani, E.,
Vanoni, M.,
Zippel, R.,
Coccetti, P.,
Brambilla, R.,
Ferrari, C.,
Sturani, E.,
and Alberghina, L.
(1992)
EMBO J.
11,
2151-2157
4.
Shou, C.,
Farnsworth, C. L.,
Neel, B. G.,
and Feig, L. A.
(1992)
Nature
358,
351-354
5.
Wei, W.,
Mosteller, R. D.,
Sanyal, P.,
Gonzales, E.,
McKinney, D.,
Dasgupta, C.,
Li, P.,
Liu, B.,
and Broek, D.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
7100-7104
6.
Cen, H.,
Papageorge, A. G.,
Zippel, R.,
Lowy, D. R.,
and Zhang, K.
(1992)
EMBO J.
11,
4007-4015
7.
Guerrero, C.,
Rojas, J. M.,
Chedid, M.,
Esteban, L. M.,
Zimonjic, D. B.,
Popescu, N. C.,
Font de Mora, J.,
and Santos, E.
(1996)
Oncogene
12,
1097-1107
8.
Feig, L. A.
(1994)
Curr. Opin. Cell Biol.
6,
204-211
9.
Whitehead, I. P.,
Campbell, S.,
Rossmann, K. L.,
and Der, C. J.
(1997)
Biochim. Biophys. Acta
1332,
F1-F23
10.
Cerione, R. A.,
and Zheng, Y.
(1996)
Curr. Biol.
8,
216-222
11.
Van Aelst, L.,
and D'Souza-Schorey, C.
(1997)
Genes Dev.
11,
2295-2322
12.
Miki, T.,
Smith, C. L.,
Long, J. E.,
Eva, A.,
and Fleming, T. P.
(1993)
Nature
362,
462-465
13.
Lemmon, M. A.,
Fergusson, K. M.,
and Schlessinger, J.
(1996)
Cell
85,
621-624
14.
Cen, H.,
Papageorge, A. G.,
Vass, W. C.,
Zhang, K.,
and Lowy, D. R.
(1993)
Mol. Cell. Biol.
13,
7718-7724
15.
Marttingly, R. R.,
and Macara, I. G.
(1996)
Nature
382,
268-272
16.
Shou, C.,
Wurmser, A.,
Ling, K.,
Barbacid, M.,
and Feig, L. A.
(1995)
Oncogene
10,
1887-1893
17.
Zippel, R.,
Orecchia, S.,
Sturani, E.,
and Martegani, E.
(1996)
Oncogene
12,
2697-2703
18.
Cheney, R. E.,
and Mooseker, M. S.
(1994)
Mol. Biol. Cell
5 (suppl.),
21a
19.
Farnsworth, C. L.,
Freshney, N. W.,
Rosen, L. B.,
Gosh, A.,
Greenberg, M. E.,
and Feig, L. A.
(1995)
Nature
376,
524-527
20.
Buchsbaum, R.,
Telliez, J.,
Gooneskera, S.,
and Feig, L.
(1996)
Mol. Cell. Biol.
16,
4888-4896
21.
Freshney, N. W.,
Gooneskera, S. D.,
and Feig, L. A.
(1997)
FEBS Lett.
407,
111-115
22.
Coso, O. A.,
Chiariello, M., Yu, J. C.,
Teramoto, H.,
Crespo, P.,
Xu, N.,
Miki, T.,
and Gutkind, J. S.
(1995)
Cell
81,
1137-1146
23.
Wigler, M. S.,
Silverstein, L. S.,
Lee, S.,
Pellicer, A.,
Cheng, Y.,
and Axel, R.
(1977)
Cell
11,
223-232
24.
Ajenjo, N.,
Aaronson, D. S.,
Ceballos, E.,
Richard, C.,
León, J.,
and Crespo, P.
(2000)
J. Biol. Chem.
275,
7189-7197
25.
Laudanna, C.,
Campbell, J. J.,
and Butcher, E.
(1996)
Science
271,
981-983
26.
Crespo, P.,
Schuebel, K. E.,
Ostrom, A. A.,
Gutkind, J. S.,
and Bustelo, X. R.
(1997)
Nature
385,
169-172
27.
Byrne, J. L.,
Paterson, H. F.,
and Marshall, C. J.
(1996)
Oncogene
13,
2055-2065
28.
Manser, E.,
Loo, T. H.,
Koh, C. G.,
Zhao, Z. S.,
Chen, X. Q.,
Tan, L.,
Tan, I.,
Leung, T.,
and Lim, L.
(1999)
Mol. Cell
1,
183-192
29.
Crespo, P.,
Xu, N.,
Simonds, W. F.,
and Gutkind, J. S.
(1994)
Nature
369,
418-420
30.
Khosravi-Far, R.,
Chrzanowska-Wodnicka, M.,
Solski, P. A.,
Eva, A.,
Burridge, K.,
and Der, C. J.
(1994)
Mol. Cell. Biol.
14,
6848-6857
31.
Feig, L. A.,
and Cooper, G. M.
(1988)
Mol. Cell. Biol.
8,
3235-3243
32.
Teramoto, H.,
Crespo, P.,
Coso, O. A.,
Igishi, T.,
Xu, N.,
and Gutkind, J. S.
(1996)
J. Biol. Chem.
271,
25731-25734
33.
Crews, C. M.,
Alessandrini, M. A.,
and Erikson, R. L.
(1992)
Science
257,
478-480
34.
Horii, Y.,
Beeler, J. F.,
Sakaguchi, K.,
Tachibana, M.,
and Miki, T.
(1994)
EMBO J.
13,
4776-4786
35.
Chen, R. H.,
Corbalan-Garcia, S.,
and Bar-Sagi, D.
(1997)
EMBO J.
16,
1351-1359
36.
Feig, L. A.
(1999)
Nat. Cell Biol.
1,
25-27
37.
Leevers, S. J.,
Paterson, H. F.,
and Marshall, C. J.
(1994)
Nature
369,
411-414
38.
Zheng, Y.,
Zangrilli, D.,
Cerione, R. A.,
and Eva, A.
(1996)
J. Biol. Chem.
271,
19017-19020
39.
Qian, X.,
Vass, W. C.,
Papageorge, A. G.,
Anborgh, P. H.,
and Lowy, D. R.
(1998)
Mol. Cell. Biol.
18,
771-778
40.
Font de Mora, J.,
Guerrero, C.,
Mahadevan, D.,
Coque, J. J. R.,
Rojas, J. M.,
Esteban, L. M.,
Rebecchi, M.,
and Santos, E.
(1996)
J. Biol. Chem.
271,
18272-18276
41.
Anborgh, P. H.,
Qian, X.,
Papageorge, A. G.,
Vass, W. C.,
DeClue, J. E.,
and Lowy, D. R.
(1999)
Mol. Cell. Biol.
19,
4611-4622
42.
Hart, M. J.,
Eva, A.,
Zangrilli, D.,
Aaronson, S. A.,
Evans, T.,
Cerione, R. A.,
and Zheng, Y.
(1994)
J. Biol. Chem.
269,
62-65
43.
Fan, W.,
Koch, C. A.,
de Hoog, C. L.,
Fam, N. P.,
and Moran, M. F.
(1998)
Curr. Biol.
8,
935-938
44.
Movilla, N.,
and Bustelo, X. R.
(1999)
Mol. Cell. Biol.
19,
7870-7885
45.
Kiyono, M.,
Satoh, T.,
and Kaziro, Y.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
4826-4831
46.
Kiyono, M.,
Kaziro, Y.,
and Satoh, T.
(2000)
J. Biol. Chem.
275,
5441-5446
47.
King, A. J.,
Sun, H.,
Diaz, B.,
Barnard, D.,
Miao, W.,
Bagrodia, S.,
and Marshall, M. S.
(1998)
Nature
396,
180-183
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
D. D. Tang and Y. Anfinogenova Physiologic Properties and Regulation of the Actin Cytoskeleton in Vascular Smooth Muscle Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2008; 13(2): 130 - 140. [Abstract] [PDF] |
||||
![]() |
T.-N. Zhu, H.-J. He, S. Kole, T. D'Souza, R. Agarwal, P. J. Morin, and M. Bernier Filamin A-mediated Down-regulation of the Exchange Factor Ras-GRF1 Correlates with Decreased Matrix Metalloproteinase-9 Expression in Human Melanoma Cells J. Biol. Chem., May 18, 2007; 282(20): 14816 - 14826. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Matallanas, V. Sanz-Moreno, I. Arozarena, F. Calvo, L. Agudo-Ibanez, E. Santos, M. T. Berciano, and P. Crespo Distinct Utilization of Effectors and Biological Outcomes Resulting from Site-Specific Ras Activation: Ras Functions in Lipid Rafts and Golgi Complex Are Dispensable for Proliferation and Transformation Mol. Cell. Biol., January 1, 2006; 26(1): 100 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. N. Robinson, K. Manto, R. J. Buchsbaum, J. I. S. MacDonald, and S. O. Meakin Neurotrophin-dependent Tyrosine Phosphorylation of Ras Guanine-releasing Factor 1 and Associated Neurite Outgrowth Is Dependent on the HIKE Domain of TrkA J. Biol. Chem., January 7, 2005; 280(1): 225 - 235. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Bryan, V. Kumar, L. J. Stafford, Y. Cai, G. Wu, and M. Liu GEFT, A Rho Family Guanine Nucleotide Exchange Factor, Regulates Neurite Outgrowth and Dendritic Spine Formation J. Biol. Chem., October 29, 2004; 279(44): 45824 - 45832. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Arozarena, D. Matallanas, M. T. Berciano, V. Sanz-Moreno, F. Calvo, M. T. Munoz, G. Egea, M. Lafarga, and P. Crespo Activation of H-Ras in the Endoplasmic Reticulum by the RasGRF Family Guanine Nucleotide Exchange Factors Mol. Cell. Biol., February 15, 2004; 24(4): 1516 - 1530. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yang, D. Cooley, J. E. Legakis, Q. Ge, R. Andrade, and R. R. Mattingly Phosphorylation of the Ras-GRF1 Exchange Factor at Ser916/898 Reveals Activation of Ras Signaling in the Cerebral Cortex J. Biol. Chem., April 4, 2003; 278(15): 13278 - 13285. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Matallanas, I. Arozarena, M. T. Berciano, D. S. Aaronson, A. Pellicer, M. Lafarga, and P. Crespo Differences on the Inhibitory Specificities of H-Ras, K-Ras, and N-Ras (N17) Dominant Negative Mutants Are Related to Their Membrane Microlocalization J. Biol. Chem., February 7, 2003; 278(7): 4572 - 4581. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-J. Rabiet, M. Tardif, L. Braun, and F. Boulay Inhibitory effects of a dominant-interfering form of the Rho-GTPase Cdc42 in the chemoattractant-elicited signaling pathways leading to NADPH oxidase activation in differentiated HL-60 cells Blood, August 13, 2002; 100(5): 1835 - 1844. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Arozarena, D. Matallanas, and P. Crespo Maintenance of Cdc42 GDP-bound State by Rho-GDI Inhibits MAP Kinase Activation by the Exchange Factor Ras-GRF. EVIDENCE FOR Ras-GRF FUNCTION BEING INHIBITED BY Cdc42-GDP BUT UNAFFECTED BY Cdc42-GTP J. Biol. Chem., June 8, 2001; 276(24): 21878 - 21884. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||